335080-41-6
Chemical Structure
Salivaricin B
- CAS No.: 335080-41-6
- Formula:C120H182N34O36S4
- Molecular Weight:2805.20
SMILES: C([C@@H](C(N[C@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@@H](CC2=CC=CC=C2)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CO)=O)CS)=O)CS)=O)[C@@H](C)O)=O)=O)CC(C)C)=O)=O)CCC(N)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC3=CN=CN3)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC(CNC(CN)=O)=O)=O)C(C)C)=O)[C@H](CC)C)=O)CCC(N)=O)=O)[C@@H](C)O)=O)[C@H](CC)C)=O)CO)=O)=O)CCC(O)=O)=O)CS)=O)CCCNC(=N)N)=O)CCSC)=O)CC(N)=O)=O)CO)=O)C=4C=5C(NC4)=CC=CC5
Biological Activity: Salivaricin B is a broad-spectrum bacteriocin produced by Lactobacillus M7. Salivaricin B reduces cell wall thickness, induces abnormal septum formation, and exerts rapid bactericidal activity against susceptible Gram-positive bacteria without disrupting cytoplasmic membrane integrity or dissipating membrane potential. Salivaricin B inhibits the growth of oral, upper respiratory tract and food-related Gram-positive pathogens, spoilage bacteria, lactobacilli, and SboB-non-producing Streptococcus salivarius strains. Its activity is strain-dependent, and it has no effect on Gram-negative bacteria. Salivaricin B can be used in studies related to bacterial infections[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Salivaricin B | 92.35% | Salivaricin B is a broad-spectrum bacteriocin produced by Lactobacillus M7. Salivaricin B reduces cell wall thickness, induces abnormal septum formation, and exerts rapid bactericidal activity against susceptible Gram-positive bacteria without disrupting cytoplasmic membrane integrity or dissipating membrane potential. Salivaricin B inhibits the growth of oral, upper respiratory tract and food-related Gram-positive pathogens, spoilage bacteria, lactobacilli, and SboB-non-producing Streptococcus salivarius strains. Its activity is strain-dependent, and it has no effect on Gram-negative bacteria. Salivaricin B can be used in studies related to bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Barbour A, et al. New insights into the mode of action of the lantibiotic salivaricin B. Scientific reports. 2016 Aug 16;6:31749.
- [2]. ten Brink B, et al. Antimicrobial activity of lactobacilli: preliminary characterization and optimization of production of acidocin B, a novel bacteriocin produced by Lactobacillus acidophilus M46. The Journal of applied bacteriology. 1994 Aug;77(2):140-8. [Content Brief]
- [3]. Hyink O, et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Applied and environmental microbiology. 2007 Feb;73(4):1107-13.
Keywords
